Recent Updates
Recently added Catalysts
MPLT Positive Sentiment

MapLight Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Key Takeaway: MapLight Therapeutics announced its participation in several upcoming investor conferences in March 2026. The events include the Jefferies Biotech on the Beach Summit, the Leerink Global Healthcare Conference, and the Stifel Virtual CNS Forum. The company aims to engage with investors through presentations and one-on-one meetings, highlighting its focus on central nervous system disorders.
Price reaction · baseline $17.27 (2026-02-27 close) · hit pre-market · clean, no other MPLT news in the window
day 0 close · peak
+1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor conferences.
  • Opportunity for 1x1 meetings with investors.
  • Focus on addressing central nervous system disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+154%
120-day peak, hindsight
Typical move
5.2%
average across 2 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
ML-007C-MA
Phase 2 · Schizophrenia

Full Press Release Details

SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:

Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings

Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings

Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website athttps://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
For more information, please visitwww.maplightrx.com.

For investor inquiries:investors@maplightrx.com

For media inquiries:media@maplightrx.com

Frequently Asked Questions

Which conferences will MapLight Therapeutics attend?

MapLight Therapeutics will attend the Jefferies Biotech Summit, Leerink Global Healthcare Conference, and Stifel Virtual CNS Forum.

What is the focus of MapLight Therapeutics?

MapLight Therapeutics focuses on improving treatments for patients with central nervous system disorders.

When is the Jefferies 2026 Biotech Summit?

The Jefferies 2026 Biotech on the Beach Summit is scheduled for March 10, 2026.

How can investors access the conference webcasts?

Investors can access live webcasts and recordings on the company's Events & Presentations page.

Last updated: Mar 2, 2026